Mid-trimester maternal serum AFP levels in predicting adverse pregnancy outcome

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Biochemistry

Background:

• Maternal serum alpha-fetoprotein (MSAFP) is a biomarker used in prenatal screening.
• Elevated MSAFP levels can sometimes indicate potential pregnancy complications.
• Understanding the predictive value of MSAFP in diverse populations is crucial for accurate risk assessment.

Purpose of the Study:

• To investigate the association between mid-trimester maternal serum alpha-fetoprotein (MSAFP) levels and adverse pregnancy outcomes.
• To assess the predictive value of MSAFP screening in a South-Western Greek population.
• To explore potential markers for identifying pregnancies at risk of complications.

Main Methods:

• Prospective study involving 110 healthy Greek women with spontaneous pregnancies.
• Measurement of maternal serum alpha-fetoprotein (MSAFP) levels between 13-24 weeks of gestation.
• Definition of abnormal MSAFP as levels > 2.0 multiples of the median; statistical analysis using Pearson's chi-square test.

Main Results:

• Elevated MSAFP levels were detected in 24.5% (27/110) of the women studied.
• Only 14.8% (4/27) of women with elevated MSAFP experienced adverse pregnancy outcomes.
• The study found a low incidence of complications among women with elevated MSAFP levels.

Conclusions:

• Elevated mid-trimester maternal serum alpha-fetoprotein (MSAFP) levels in this Greek population were not strongly predictive of adverse pregnancy outcomes.
• Multiparameter testing, including uterine artery Doppler and placental morphology, may offer a more comprehensive approach to identifying high-risk pregnancies.
• Further research is needed to validate multiparameter screening for placental insufficiency.